Clinical Trial Update: A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating abiraterone acetate plus prednisone with or without exemestane in postmenopausal women with estrogen receptor-positive metastatic breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Exemestane (Exemestane)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Metastatic ER+ Her2- Breast Cancer, Postmenopausal | Phase 2 | Status: COMPLETED | Results posted: 2018-07-27